JAZZ News and Press, Jazz Pharmaceuticals plc From 11/04/20

The following slide deck was published by Jazz Pharmaceuticals plc in conjunction with their 2020 Q3 earnings call. For further details see: Jazz Pharmaceuticals plc 2020 Q3 - Results - Earnings Call Presentation

Jazz Pharmaceuticals plc (JAZZ) Q3 2020 Results Earnings Conference Call November 2, 2020, 4:30 PM ET Company Participants Kathy Littrell - Head, Investor Relations Bruce Cozadd - Chief Executive Officer Renée Galá - Chief Financial Officer Dan Swisher - President Rob Iannone - Exec...

Jazz Pharmaceuticals (JAZZ): Q3 Non-GAAP EPS of $4.31 beats by $0.23; GAAP EPS of $2.64 misses by $0.31.Revenue of $600.89M (+11.8% Y/Y) beats by $23.27M.Raises 2020 Guidance: Revenues: $2.32B - 2.38B; Total net product sales: $2.3B - 2.36B; Adj. gross margin: 94%; EPS: $3.70 - 4.85; non...

Jazz Pharmaceuticals Announces Third Quarter 2020 Financial Results Strong Financial and Operational Performance in Third Quarter 2020 Total Revenues Increased 12% Compared to Third Quarter 2019 Strong Demand for Zepzelca Following July Launch Launched Xywav for Narc...

Jazz Pharmaceuticals (NASDAQ:JAZZ) is scheduled to announce Q3 earnings results on Monday, November 2nd, after market close.The consensus EPS Estimate is $4.08 (-0.5% Y/Y) and the consensus Revenue Estimate is $577.62M (+7.4% Y/Y).Over the last 2 years, JAZZ has beaten EPS estimates 88% of th...

Jazz Pharmaceuticals ([[JAZZ]] -0.6%) and SpringWorks Therapeutics ([[SWTX]] +0.7%) entered into an asset purchase and exclusive license agreement wherein the former has acquired the latter's fatty acid amide hydrolase ((FAAH)) inhibitor program including PF-04457845.SpringWorks has also assi...

Jazz Pharmaceuticals Acquires SpringWorks Therapeutics' FAAH Inhibitor Program Jazz Gains Exclusive Global Rights to FAAH Inhibitor PF-04457845 for the Potential Treatment of PTSD Strategically Expands Jazz's Mid-Stage Neuroscience Pipeline into a New Disease Area and Furthe...

Bank of America has 10 US Idea stocks selected as outperformers during a quarter that includes huge stimulus, election and COVID wildcards.BofA says the picks for Q4 are based on its views of potential significant market and business-related catalysts that it thinks will affect the stocks dur...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

NLS Pharmaceutics has filed to raise $20 million in a U.S. IPO. The firm is advancing treatments for narcolepsy and ADHD. NLSP is thinly capitalized and has made no apparent progress on beginning trials for its lead candidate, so I'll pass on the IPO. For further details see...